CDK4 and serous adenocarcinoma: In a recent pilot study, NACT with antiestrogenic therapy and a CDK4/6 inhibitor for unresectable, untreated stage III to IV low-grade serous carcinomas demonstrated an unprecedented response rate (clinical benefit rate, 80%).36 Further development in a larger study population is warranted.